Page last updated: 2024-10-22

amlodipine and Diarrhea

amlodipine has been researched along with Diarrhea in 4 studies

Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.

Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.

Research Excerpts

ExcerptRelevanceReference
" The authors report on an 8-week double-blind, randomized study of African American patients with stage 2 hypertension that compared brachial and central BP responses (substudy of 53 patients) to combination aliskiren/hydrochlorthiazide (HCTZ) and amlodipine monotherapy."9.15Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial. ( Ferdinand, KC; Pool, J; Purkayastha, D; Townsend, R; Weitzman, R, 2011)
"Eplerenone is a highly selective aldosterone blocker, which is under development for the treatment of hypertension and heart failure."9.10Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. ( Duprez, D; Krause, S; Kuse-Hamilton, J; Roniker, B; St Hillaire, R; Weber, MA; White, WB, 2003)
" The authors report on an 8-week double-blind, randomized study of African American patients with stage 2 hypertension that compared brachial and central BP responses (substudy of 53 patients) to combination aliskiren/hydrochlorthiazide (HCTZ) and amlodipine monotherapy."5.15Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial. ( Ferdinand, KC; Pool, J; Purkayastha, D; Townsend, R; Weitzman, R, 2011)
"Eplerenone is a highly selective aldosterone blocker, which is under development for the treatment of hypertension and heart failure."5.10Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. ( Duprez, D; Krause, S; Kuse-Hamilton, J; Roniker, B; St Hillaire, R; Weber, MA; White, WB, 2003)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Roffey, E1
Bhurawala, H1
Turcu, AF1
White, JA1
Kulaga, ME1
Skluth, M1
Gruss, CB1
Ferdinand, KC1
Pool, J1
Weitzman, R1
Purkayastha, D1
Townsend, R1
White, WB1
Duprez, D1
St Hillaire, R1
Krause, S1
Roniker, B1
Kuse-Hamilton, J1
Weber, MA1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An 8 Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ Versus Amlodipine in African American Patients With Stage 2 Hypertension[NCT00739596]Phase 4332 participants (Actual)Interventional2008-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percentage of Participants Achieving BP Control After 8 Weeks of Treatment

To compare the percentage of patients achieving BP control (<140/90 mm Hg) after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension. (NCT00739596)
Timeframe: 8 weeks

InterventionCumulative percentage of participants (Number)
Aliskiren HCTZ63.6
Amlodipine62.3

Percentage of Responders After 8 Weeks of Treatment.

To compare the percentage of responders after 8 weeks of treatment with an aliskiren HCTZ based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension: [ Responders were defined as patients with MSSBP < 140 mm Hg or a decrease from baseline ≥ 20 mm Hg at 1st response. A response was counted when a patient first achieved MSSBP < 140 mm Hg or a decrease from baseline ≥ 20 mm Hg.] (NCT00739596)
Timeframe: 8 weeks

InterventionCumulative percentage of responders (Number)
Aliskiren HCTZ84.6
Amlodipine90.7

Change in Mean Sitting Diastolic Blood Pressure (MSDBP) After 8 Weeks of Treatment

To assess the change from baseline in mean sitting diastolic blood pressure (MSDBP) after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension. (NCT00739596)
Timeframe: Baseline and 8 weeks

,
Interventionmm Hg (Mean)
BaselineWeek 8Change from Baseline to Week 8
Aliskiren HCTZ96.086.0-10.0
Amlodipine95.084.0-11.0

Change in Mean Sitting Pulse Pressure (MSPP) After 8 Weeks of Treatment

To compare the change from baseline in mean sitting pulse pressure (MSPP) after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension. (NCT00739596)
Timeframe: Baseline and 8 weeks

,
Interventionmm Hg (Mean)
BaselineWeek 8Change from Baseline to Week 8
Aliskiren HCTZ72.252.7-19.4
Amlodipine73.155.1-18.0

Change in Mean Sitting Systolic Blood Pressure (MSSBP) After 8 Weeks of Treatment

To assess the change from baseline in MSSBP after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension. (NCT00739596)
Timeframe: Baseline and 8 weeks

,
Interventionmm Hg (Mean)
BaselineWeek 8Change from baseline to Week 8
Aliskiren HCTZ168.2138.8-29.4
Amlodipine168.1139.1-29.0

Reviews

1 review available for amlodipine and Diarrhea

ArticleYear
Calcium channel blocker-associated small bowel angioedema.
    Journal of clinical gastroenterology, 2009, Volume: 43, Issue:4

    Topics: Abdominal Pain; Amlodipine; Angioedema; Calcium Channel Blockers; Diarrhea; Female; Humans; Intestin

2009

Trials

2 trials available for amlodipine and Diarrhea

ArticleYear
Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial.
    Journal of clinical hypertension (Greenwich, Conn.), 2011, Volume: 13, Issue:5

    Topics: Adult; Amides; Amlodipine; Antihypertensive Agents; Black or African American; Blood Pressure; Brach

2011
Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
    Hypertension (Dallas, Tex. : 1979), 2003, Volume: 41, Issue:5

    Topics: Aged; Albuminuria; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channe

2003

Other Studies

1 other study available for amlodipine and Diarrhea

ArticleYear
The hypertensive child.
    Australian journal of general practice, 2019, Volume: 48, Issue:12

    Topics: Abdominal Pain; Adrenocorticotropic Hormone; Aldosterone; Amlodipine; Antihypertensive Agents; Catec

2019